clinical trial · NCT01922440
A Registry for Participants With Chronic Hypoparathyroidism
Takeda·—·active not recruiting·n = 1,339
HypoparathyroidismNo intervention
brief summary
The main aim of this study is to find out the long-term safety and effectiveness profile of recombinant human parathyroid hormone (1-84) (rhPTH\[1-84\]) treatment in participants with chronic hypoparathyroidism under conditions of routine clinical practice. Participants will be treated according to their clinic's standard practice determined by the treating doctors. Each participant will fill out a study questionnaire during a routine doctor visit.
started
Jul 30, 2013
primary completion
Nov 30, 2034
completion
Nov 30, 2034
last updated
Sep 29, 2025
official title
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol